U.S. Patent No. 10,456,435 B2

Cannabis IP patent

U.S. Patent No. 10,456,435 B2 (‘435) issued on October 29, 2019, entitled ”Topical Antiviral Formulations and Methods of Using the Same.”  It was issued to applicant/inventor Christopher A. McElvany of Denver, Colorado.

The specification discloses an antiviral composition for treatment of herpes simplex virus (HSV), or the common cold sore.  The sole claim in the ‘435 patent is directed to the apparatus, or a stick or pen consisting essentially of a cannabinoid, tea tree oil, beeswax, lanolin wax, and cocoa butter.

There were no drawings submitted with the application.

The Cooperative Patent Classification is A61K, preparations for medical, dental, or toilet purposes, namely, medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, namely, magnoliopsida (36/185), medical preparations characterized by special physical form, namely, galenical aspects of topical compositions (9/0014), emulsions (9/107), and microcapsules (9/50), medical preparations containing organic active ingredients, namely, phenols (31/05) condensed with carbocyclic rings (31/352) of acyclic acids, e.g., pravastatin (31/22), and medicinal preparations characterized by the non-active ingredients used, e.g., carriers or inert additives, namely, alcohols, phenols, salts thereof (47/10) and oils, fats or waxes according to two or more groups (47/44).

The ‘435 patent illustrates patent availability for cannabis-based topicals or creams.  Cannabis patents still represent a huge growth area for patent procurement and development, as the legalized industry is still in its infancy throughout much of the country.  Please contact Yonaxis for more information or if you have any questions.